A series of peptide derivatives based on the transition-state mimetic concept has been designed that inhibit the proteinase from the human immunodeficiency virus (HIV). The more active compounds inhibit both HIV-1 and HIV-2 proteinases in the nanomolar range with little effect at 10 micromolar against the structurally related human aspartic proteinases. Proteolytic cleavage of the HIV-1 gag polyprotein (p55) to the viral structural protein p24 was inhibited in chronically infected CEM cells. Antiviral activity was observed in the nanomolar range (with one compound active below 10 nanomolar) in three different cell systems, as assessed by p24 antigen and syncytium formation. Cytotoxicity was not detected at 10 of HIV, gag andgag-pol gene products are translated as polyproteins. These are subsequently processed by a virally encoded proteinase to yield structural proteins of the virus core (p17, p24, p9, and p7), together with essential viral enzymes including the proteinase itself (1). On the basis of its primary amino acid sequence (1), its inhibition by pepstatin (2), and its crystal structure (3), HIV-1 proteinase has been classified as an aspartic proteinase that functions as a homodimer (4). This enzyme was first suggested as a potential target for AIDS therapy by Kramer et al. (5) when it was shown that a frameshift mutation in the proteinase region of the pol gene prevented processing of the gag polyproptein precursor. In this report we describe the rational design of a series of potent, selective inhibitors of HIV proteinase that show powerful antiviral activity against HIV-1 in vitro combined with low cytotoxicity to the host cell lines.
Although HIV proteinase can cleave a number of specific peptide bonds (6), it is unusual in being able to cleave the Phe-Pro and Tyr-Pro sequences found in gag and gagpol gene products. Since the amide bonds of Pro residues are not susceptible to cleavage by mammalian endopeptidases, we reasoned that this could provide a basis for the rational design of HIV proteinase inhibitors selective for the viral enzyme.
Our strategy was based on the transitionstate mimetic concept, an approach that has been used successfully in the design of potent inhibitors of other aspartic proteinases. Transition-state mimetics include hydroxyethylene isosteres (7), phosphinic acid (8), reduced amide (9), statine types (10) , and hydroxyethylamine mimetics (11) . Since the reduced amide I and the hydroxyethylamine II structures (Fig. 1) Having identified compound IV as being of the minimum size required for potent inhibition, we systematically explored the structural requirements for optimal binding at each subsite. More than 100 compounds were synthesized in which the steric and electronic properties of each side chain and terminal substituent were individually modified. The most important findings were that a large hydrophobic pocket at P3 was inferred from the high potency shown by compounds X and XI. At the P2 subsite no improvement over asparaginyl was found, although the P-cyanoalanyl and S-methylcysteinyl analogues, compounds XIII and XVI, respectively, displayed comparable potencies. Similarly, at P1 no improvement was found over the benzyl side chain of Phe. The most marked improvements in potency were achieved by varying the imino acid at P1, highly effective replacements for prolyl being piperidine-2-(S)-carbonyl (compound XII) and (S,S,S)-decahydro-isoquinoline-3- 20 APRIL 1990 carbonyl (compound XVII). At the carboxyl terminus tert-butyl ester could be replaced by a tert-butylamide group without significant change in potency (compounds IV and IX), but no better replacement was identified.
Incorporating combinations of preferred side chains into individual molecules resulted in the generation of several very potent inhibitors of both HIV-1 and HIV-2 proteinases, for example, compounds XIV and XVII. The inhibition constant Ki for compound XVII atpH 5.5 was 0.12 nM against HIV-1 proteinase, and binding to HIV-2 proteinase was even stronger (Ki < 0.1 nM). It was important to confirm that inhibitors optimized in an assay using a small synthetic substrate were also effective in blocking the cleavage of the natural gag polyprotein substrate. In a mixed bacterial lysate assay, compound XVII at 1 ,pM completely inhibited the processing of HIV-1 gag polyprotein by HIV-1 and HIV-2 proteinases as assessed by immunoblot analysis (Fig. 2A) . Moreover, this compound was highly selective, causing less than 50% inhibition of the human aspartic proteinases renin, pepsin, gastricsin, cathepsin D, and cathepsin E (14) at a concentration of 10
FxM. In addition, compound XVII at a concentration of 10 FLM had no effect on representative proteinases from the serine, cysteine, and metallo classes [such as human leucocyte elastase, bovine cathepsin B, and human collagenase, respectively (15)].
The antiviral activities of compounds in this series correlated well with their potencies as proteinase inhibitors ( Table 2) . The most potent antiviral activity was observed with compound XVII, which had a 50% inhibition concentration (ICso) of 2 nM against HIV-1 (strain RF) in C8166 cells as assessed by measurement of viral antigen (p24) in the culture medium. When the multiplicity of infection was increased tenfold from 10 to 100 TCID50 (median tissue culture infectious dose) units per 2 x 105 cells, there was only a marginal effect on the IC50 values for compounds IV and XVII (Table 2 ). In this test system the IC50 for azidothymidine (AZT) was in the range 3 to 30 nM, which is similar to the IC50 for AZT reported (16) against HIV isolates from untreated AIDS or ARC patients using a plaque assay (10 to 50 nM) or p24 antigen levels (<30 nM). The antiviral potencies of compounds IV, XIV, and XVII were confirmed in JM cells infected with the HIV-1 Table 1 . HIV-1 and HIV-2 proteinases were cloned, expressed, and purified as previously described ( 
